Skip to main
SER

SER Stock Forecast & Price Target

SER Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Serina Therapeutics Inc is advancing its pipeline of drug candidates, specifically highlighting the potential impact of SER-270, which, if successful, could significantly enhance the company's valuation beyond current assessments based solely on SER-252. The company's proprietary POZ Platform delivery technology offers innovative advantages that can better address the challenges associated with drug development, particularly for neurological diseases and pain management. Additionally, the expanding approval footprint of enFuse suggests positive long-term market acceptance for SER-252, supporting a fundamentally optimistic outlook for the company's future financial performance.

Bears say

Serina Therapeutics reported a net loss of $0.64 per share, significantly higher than the original estimate of $0.36, indicating a worsening financial position as it prepares for full-year 2025 losses projected at $2.01 per share. The company faces multiple risks, including delays in advancing SER-252 into clinical trials, challenges in achieving regulatory approval, and competition that may hinder market uptake. Additionally, potential future partnership risks and the possibility of dilution could further undermine investor confidence in the stock.

SER has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Serina Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Serina Therapeutics, Inc. (SER) Forecast

Analysts have given SER a Strong Buy based on their latest research and market trends.

According to 2 analysts, SER has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Serina Therapeutics, Inc. (SER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.